TOFACITINIB

Information current as at: 1 June 2026

PBAC meeting date: November 2020

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: Xeljanz®
Form and strength:: Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:: Pfizer Australia Pty Ltd
Condition/indication: (therapeutic use): Chronic plaque psoriasis Psoriatic arthritis Rheumatoid arthritis Ulcerative arthritis
Listing requested:: Please see PSD for more information
Funding program:: Please see PSD for more information
Request authority level:: Please see PSD for more information
PBAC Submission type:: Change to recommended listing (Minor)
Comment:: The PBAC decided to advise the Minister (under section 101(3BA) of the National Health Act 1953 (“the Act”)) that tofacitinib should be treated as interchangeable on an individual patient basis with other drugs or medicinal preparations.
Other PBAC consideration:: TOFACITINIB

Submission received for::: November 2020 PBAC meeting
Opportunity for consumer comment:: Open 24/12/2019 and close 12/02/2020 (see PBS Website)
PBAC meeting:: Held on 04/11/2020
PBAC outcome published:: Not Applicable (see PBAC Outcomes)
Lodgement of required documentation:: Not applicable
Agreement to listing arrangements:: Not applicable
Government processes:: Not applicable
Medicine listed on the PBS:: Not applicable

PBAC Recommendation:

Please see the Outcomes from the relevant meeting for more information

Case ID

a275

Page last updated

31 March 2026

v.9.19